ReviewPharmaceutics2022

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab.

Ana Maria Lé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.